Search

everythinglearnresearchcommunity

for

Search:↓

A user applied tretinoin to their scalp for hair loss and found brown particles in the cream. They are seeking information about these particles.

Dutasteride may affect testosterone levels, leading to high ferritin and iron levels, which can cause hair loss. High ferritin might be linked to past heavy drinking or hemochromatosis.

Kintor 0.9% is not effective for hair regrowth or thickening and may cause testicle sensitivity. The conversation criticizes the hype around Kintor and discusses the ineffectiveness of pyrilutamide compared to other treatments like RU58841, finasteride, and minoxidil.

User creates 0.1% topical finasteride solution using Alfatradiol Avixis base. Seeks help to ensure alfatradiol base dissolves finasteride.

RU58841 is effective when used once daily. Using it twice daily may require reducing the dosage, potentially decreasing its effectiveness.

The user started finasteride two weeks ago and has been using minoxidil for over a month, while also supplementing with Acetyl L-Carnitine. They are curious if others have experienced hair shedding or growth with Acetyl L-Carnitine, especially when used with finasteride and minoxidil.

The user used 0.5 mL of 0.5 mg of Pyrilutamide for 60 days for hair loss, but didn't notice any hair growth. They shared their hormone panel results and are seeking advice on next steps.

The user is using Dutasteride, Nizoral, and RU58841 for hair loss and is considering mixing RU58841 with Stemoxydine for better scalp coverage but is concerned about the potential degradation of RU58841 when mixed with a water-based solution. They are seeking advice on the feasibility of this mixture.

The conversation is about a person's hair improvement after 14.5 months using RU58841 and Minoxidil topically at 50 mg each day, with noticeable hairline improvement but incomplete crown area recovery. The person struggles to take good pictures of their crown area.

The conversation is about making a solution of RU58841 using propanediol instead of propylene glycol due to skin irritation. The user seeks advice on whether this substitution is acceptable.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. The user is considering using these alongside Pyrilutamide 0.9%.

The user switched from oral finasteride to dutasteride with minoxidil, but saw no results. They then tried topical finasteride and noticed some potential improvement after four months, theorizing that the topical application bypasses liver metabolism.

Choosing between two hair loss treatments, with a preference for a higher concentration of RU58841 and 5% minoxidil, avoiding oils like castor and argan that may hinder absorption.

The conversation is about a user trying a new hair loss treatment, Ruxolitinib, alongside their existing regimen of finasteride, minoxidil, ketoconazole shampoo, and microneedling. They plan to apply Ruxolitinib to their temples daily for 1-2 months.

The conversation discusses how Tretinoin may improve the effectiveness of Minoxidil for treating hair loss by increasing the activity of certain enzymes in hair follicles. One user comments that this information is not new.

A 21-year-old with diffuse thinning hair is considering RU58841 due to side effects from topical finasteride and is asking for the lowest effective dose and time to see results from RU58841 users.

Mixing Pyrilutamide powder with Minoxidil solution is being considered. The Minoxidil solution contains Minoxidil 5%, Azelaic acid 5%, ABN complex 0.8%, Retinol 0.025%, Caffeine 0.001%, and a delivery vehicle.

The user checked iron, ferritin, B12, zinc, testosterone, DHT, and estrogens to understand hair loss causes and the effects of dutasteride. They also noted increased heart rate and paleness with oral minoxidil.

The user is considering mixing 15mg of dutasteride with 60ml of castor oil for mesotherapy (micro-needling) to treat hair loss. They are asking if this method is viable.

Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.

The conversation discusses sourcing pyrilutamide from China for hair loss treatment, highlighting its potency compared to other AR antagonists like bicalutamide and RU58841. The user expresses interest in trying pyrilutamide despite mixed results in clinical trials.

The post and conversation are about the high cost and skepticism surrounding pyrilutamide as a hair loss treatment, with comparisons to minoxidil, finasteride, and RU58841. The original poster defends pyrilutamide's effectiveness and criticizes others for dismissing it without proper understanding.

The conversation is about using liposomal finasteride for hair loss treatment, highlighting its cost-effectiveness and ease of preparation. It suggests using lecithin and crushed finasteride pills to make the solution, which has shown to be significantly more effective than other topical formulations.

RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.

The conversation is about a product called Serioxyl, which was expected to contain stemoxydine. It clarifies that Diethyl lutidinate is another name for stemoxydine.

Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.

The user is considering starting pyrilutamide before a scheduled hair transplant, having previously used oral minoxidil and finasteride with worsening results. They also tried dutasteride, which worsened their hair and made their skin oily.

The user is using 0.1% dutasteride, 1% minoxidil with 2% procapil and 0.005% caffeine in the morning, and 1% minoxidil with 2% procapil and 0.01% tretinoin at night. They are concerned about the solution vehicle's effectiveness in preventing systemic absorption and ensuring the products stay around the hair follicles.

Doctors are testing verteporfin topically for healing and potential regeneration after transplants. The user is asking how it is formulated for topical use, such as if it's mixed with a carrier gel.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.